Early use of Uptravi reduces risk of disease progression in PAH patients
Phase III study finds risk reduced by 52% compared with control group
Read Moreby Lucy Parsons | Sep 1, 2021 | News | 0
Phase III study finds risk reduced by 52% compared with control group
Read Moreby Anna Smith | Jan 2, 2019 | News | 0
Actelion Pharmaceuticals has announced that NHS patients in England, who have the rare, incurable and devastating disease pulmonary arterial hypertension (PAH), can now be treated with Uptravi.
Read Moreby Selina McKee | Jul 9, 2018 | News | 0
Actelion’s Uptravi will not be funded on the NHS for patients with Pulmonary Arterial Hypertension (PAH), after the drug failed to make it into NHS England’s latest round of specialised commissioning approvals.
Read Moreby Selina McKee | Jun 14, 2018 | News | 0
Some patients with pulmonary arterial hypertension (PAH) are now able to access Actelion’s selexipag on the NHS in Wales after a green light from the All Wales Medicines Strategy Group (AWMSG).
Read Moreby Selina McKee | May 8, 2018 | News | 0
A new treatment option for the very rare condition infantile onset 5q spinal muscular atrophy (type I SMA) is among five medicines that have been endorsed by Scottish cost regulators for use on the NHS.
Read Moreby Selina McKee | Jul 11, 2017 | News | 0
Actelion says it is disappointed with a decision by Scottish cost regulators to refuse NHS funding for pulmonary arterial hypertension drug Uptravi.
Read Moreby Selina McKee | Apr 10, 2017 | News | 0
European regulators have ruled that Actelion’s Uptravi can continue to be used as per its prescribing information to treat patients with pulmonary arterial hypertension, a life-threatening condition involving abnormally high blood pressure in the arteries of the lungs.
Read Moreby Selina McKee | Feb 13, 2017 | News | 0
European regulators are advising that doctors can continue prescribing Actelion’s Uptravi for pulmonary arterial hypertension while an investigation into its safety is completed.
Read Moreby Selina McKee | May 17, 2016 | News | 0
EU regulators have issued a green light for Actelion’s Uptravi, offering a new treatment option to patients with pulmonary arterial hypertension.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
